DRUG
Bright Minds Biosciences Inc (DRUG)
Healthcare • NASDAQ • $85.50-3.73%
- Symbol
- DRUG
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $85.50
- Daily Change
- -3.73%
- Market Cap
- $836.80M
- Trailing P/E
- N/A
- Forward P/E
- -10.99
- 52W High
- $123.75
- 52W Low
- $23.18
- Analyst Target
- $161.57
- Dividend Yield
- N/A
- Beta
- -0.19
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the…
Company websiteResearch DRUG on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.